Monitoring the ERSPC trial

BJU International, Supplement

Volumn 92, Issue 2, 2003, Pages 112-114

  De Koning, H J ^a   Hakulinen, T ^b   Moss, S M ^c   Adolfsson, J ^d   Smith, P H ^e   Alexander, F E ^a,f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b FINNISH CANCER REGISTRY   (Finland)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Department of Public Health ^*

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Evaluation; Power calculation; Prostate cancer; Screening trial

Indexed keywords

HORMONE;

CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CAUSE OF DEATH; FOLLOW UP; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZATION; REVIEW; SIDE EFFECT; TOXICITY; TUMOR BIOPSY;

EID: 0345865054     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Koning HJ, Auvinen A, Berenguer Sanchez A et al. Large-scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer- and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002; 97: 237-44
2. The International Prostate Screening Trial Evaluation Group. Rationale for randomised trials of prostate cancer screening. Eur J Cancer 1999; 35: 262-71
3. Olsen O, Goøtzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001; 358: 1340-2
4. Koning HJ de, Liem M, Baan CA, Boer R, Schröder FH, Alexander FE. Prostate cancer mortality reduction by screening; power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002; 98: 268-73
5. Koning HJ de, Blom J, Merkelbach JW et al. Determining cause of death in randomised screening trial(s) for prostate cancer (ERSPC trial). BJU Int 2003; in press
6. Nyström L, Larsson LG, Rutqvist LE et al. Determination of cause of death among breast cancer cases in the Swedish randomized mammography screening trials. A comparison between official statistics and validation by an endpoint committee. Acta Oncol 1995; 34: 145-52
7. Koning HJ de. Mammographic screening: evidence from randomised controlled trials. Ann Oncol 2003; 14: 1185-9
8. Hakulinen T, Kenward M, Luostarinen T, Oksanen H, Pukkala E, Söderman B, Teppo L. Cancer in Finland in 1954-2008. Incidence, Mortality and Prevalence by Region. Helsinki, Finland: Finnish Cancer Registry, 1989.
9. Lenner P. The excess mortality rate. A useful concept in cancer epidemiology. Acta Oncol 1990; 29: 573-6
10. Lu-Yao GL, Albertsen P, Warren J, Yao SL. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy - a population-based study. Urology 1999; 54: 301-7
11. Draisma G, Boer R, Otto SJ et al. Lead-times and overdetection in PSA screening - an estimate based on results from the ERSPC trial. J Natl Cancer Inst 2003; 95: 868-78
12. O'Brian PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56